Cargando…
New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
Although tuberculosis (TB) is preventable and curable, the lengthy treatment (generally 6 months), poor patient adherence, high inter-individual variability in pharmacokinetics (PK), emergence of drug resistance, presence of comorbidities, and adverse drug reactions complicate TB therapy and drive t...
Autores principales: | Aguilar Diaz, Jessica M, Abulfathi, Ahmed A, te Brake, Lindsey HM, van Ingen, Jakko, Kuipers, Saskia, Magis-Escurra, Cecile, Raaijmakers, Jelmer, Svensson, Elin M, Boeree, Martin J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932851/ https://www.ncbi.nlm.nih.gov/pubmed/36516792 http://dx.doi.org/10.1159/000528274 |
Ejemplares similares
-
High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre
por: Seijger, Charlotte, et al.
Publicado: (2019) -
Treatment of severe Mycobacterium avium complex pulmonary disease with adjunctive amikacin and clofazimine versus standard regimen alone: a retrospective study
por: Zweijpfenning, Sanne M.H., et al.
Publicado: (2021) -
Epidemiology of Mycobacterium bovis Disease in Humans, the Netherlands, 1993–2007
por: Majoor, Christof J., et al.
Publicado: (2011) -
The Antipsychotic Thioridazine Shows Promising Therapeutic Activity in a Mouse Model of Multidrug-Resistant Tuberculosis
por: van Soolingen, Dick, et al.
Publicado: (2010) -
Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands
por: van Ingen, Jakko, et al.
Publicado: (2008)